Format

Send to

Choose Destination
Vaccine. 2019 Nov 22. pii: S0264-410X(19)31470-7. doi: 10.1016/j.vaccine.2019.10.081. [Epub ahead of print]

Immunogenicity and safety of vaccination against seasonal influenza vaccine in patients with psoriatic arthritis treated with secukinumab.

Author information

1
Department of Rheumatology, Tel Aviv Medical Center, Israel; The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
2
Unit of Rheumatology, Carmel Medical Center, Israel.
3
Department of Rheumatology, Tel Aviv Medical Center, Israel.
4
Central Virology Laboratory, Sheba Medical Center, Tel Hashomer, Israel; The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
5
Unit of Rheumatology, Carmel Medical Center, Israel; Central Virology Laboratory, Sheba Medical Center, Tel Hashomer, Israel.
6
Department of Rheumatology, Tel Aviv Medical Center, Israel; The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: Oribe14@gmail.com.

Abstract

OBJECTIVE:

To assess the immunogenicity and safety of vaccination against seasonal influenza in psoriatic arthritis (PsA) patients treated with secukinumab versus healthy controls (HC).

METHODS:

PsA patients administered secukinumab for ≥3 months and HC received the Sanofi Pasteur vaccine composed of 3 antigens (H3N3, H1N1, and B) and underwent clinical and laboratory assessments on the day of vaccination and 4-6 weeks later. Immunogenicity of the vaccine was evaluated by hemagglutination inhibition assay against those 3 antigens. Responders to each antigen were defined by a 4-fold increase in the antigen titer or by seroconversion in patients whose baseline level was <1/40.

RESULTS:

Thirty-two consecutive PsA patients treated with secukinumab for ≥3 months comprised the study group, 10 of whom received concomitant conventional synthetic disease-modifying drugs, mostly methotrexate. There were 17 age- and gender-matched HC (median age 48.5 years, 6 females). The geometric mean titers of each antigen increased significantly in both groups. The number of responders in each group was similar for H3N2 and H1N1, and significantly higher for B/Brisbane in the PsA group. The proportion of patients with a seroprotective level (a titer >1/40) was high and similar in both groups. There was no correlation between the response rate and age, gender, or selected parameters of disease activity (tender/swollen joint counts, Leeds enthesitis index, physician and patient global assessment, psoriasis area severity index, and C-reactive protein). No disease exacerbation was observed following the vaccination. No serious adverse effects were observed in both groups during the study period.

CONCLUSION:

Secukinumab treatment does not affect the humoral response to influenza vaccine of patients with PsA.

KEYWORDS:

Influenza vaccine; Psoriatic arthritis; Secukinumab

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center